Analysts at Nomura initiated coverage on Tetraphase Pharmaceuticals, Inc. TTPH with a Buy rating.
The target price for Tetraphase Pharmaceuticals is set to $54.
Tetraphase Pharmaceuticals shares have gained 233.05% over the past 52 weeks, while the S&P 500 index has surged 13.49% in the same period.
Tetraphase Pharmaceuticals' shares fell 4.30% to close at $39.20 on Friday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in